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Background: The purpose of this study was to evaluate prognostic value of N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with 
acute myocardial infarction (AMI) and chronic kidney disease (CKD). 
Methods: Between November 2005 and January 2008, 834 post-MI patients (560 males; mean age = 64.7 ± 11.7 year-old) followed up more 
than six-month were included. Glomerular filtration rate was estimated (eGFR) using the abbreviated Modification of Diet in Renal Disease Study 
equation. Patients were categorized into two groups according to the level of eGFR at baseline; Group 1 (eGFR <60 ml/min/1.73 m2) and Group 
2 (eGFR ≥60 ml/min/1.73 m2). The 6-month major adverse cardiac events (MACEs) were defined as a composite of death, non-fatal MI, and 
revascularizations. 
Results: During the follow-up, 57 (11.4%) MACEs occurred. Log-transformed NT-proBNP levels increased significantly with increasing eGFR grades 
and inversely correlated with eGFR in patients with (r = - 0.544, p<0.001) or without CKD (r = - 0.158, p<0.001). In multivariate Cox regression 
analysis, log-transformed NT-proBNP (hazard ratio [HR] 1.342, 95% confidence interval [CI] 1.013-1.778; p=0.040) was independent predictor for 
6-month MACEs after adjustment for confounding variables. In receiver-operator characteristic curve, the area under curve (AUC) of the NT-proBNP 
for predicting 6-month MACEs was 0.681 ± 0.040 (sensitivity 58.7%, specificity 72.3%; p<0.001), and optimum cut-off value was 10,816 pg/mL 
in Group 1, whereas the AUC of NT-proBNP was 0.732 ± 0.036 (sensitivity 72.9%, specificity 68.5%; p<0.001), and optimum cut-off value was 691 
pg/mL in Group 2. Kaplan-Meier survival curve showed patients with NT-proBNP ≥10,816 pg/mL in Group 1 (52.9% versus 23.2%; log-rank test p < 
0.001) and patients with NT-proBNP ≥691 pg/mL in Group 2 (15.6% versus 3.0%; log-rank test p < 0.001) had significantly higher 6-month MACEs. 
Conclusions: Although renal function is a significant confounder of NT-proBNP level, elevated NT-proBNP levels have clinical significance even in 
post-MI patients with CKD.
